×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Mantle Cell Lymphoma

Katie Kosko
An expert sheds light on the latest therapies in clinical trials and promising drug combinations to thwart the aggressive disease.
Jessica Skarzynski
Patients with relapsed/refractory mantle cell lymphoma saw more favorable responses with the BTK inhibitor Imbruvica (ibrutinib) than with chemotherapy, according to nearly a decade of data.
Katie Kosko
Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Kristie L. Kahl and Lee Greenberger
Lee Greenberger, chief scientific officer at the Leukemia and Lymphoma Society, discusses the basics of mantle cell lymphoma – including symptoms, diagnosis and advancing treatment options.
Kristie L. Kahl And Neena Kennedy
Neena Kennedy, from the Leukemia and Lymphoma Society, offers advice on how to find out about and join clinical trials.
Kristie L. Kahl
Here is a list of the recent trial initiations that occurred within the cancer space in January.
Dr. Simon Rule
Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.
Kristie L. Kahl
The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.
 
Kristie L. Kahl
Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×